Novavax, Inc. Stock price

Equities

NVAX

US6700024010

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
4.78 USD -1.44% Intraday chart for Novavax, Inc. -1.04% -0.42%
Sales 2024 * 850M Sales 2025 * 929M Capitalization 679M
Net income 2024 * -90M Net income 2025 * - EV / Sales 2024 * 0.2 x
Net cash position 2024 * 510M Net cash position 2025 * 482M EV / Sales 2025 * 0.21 x
P/E ratio 2024 *
-6.09 x
P/E ratio 2025 *
47.5 x
Employees 1,543
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.33%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.97%
1 week+0.41%
Current month-1.82%
1 month-19.44%
3 months-1.82%
6 months-32.55%
Current year+1.04%
More quotes
1 week
4.63
Extreme 4.63
4.92
1 month
4.38
Extreme 4.38
6.00
Current year
3.53
Extreme 3.5324
6.05
1 year
3.53
Extreme 3.5324
11.36
3 years
3.53
Extreme 3.5324
277.80
5 years
3.53
Extreme 3.5324
331.68
10 years
3.53
Extreme 3.5324
331.68
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 23-01-22
President 64 14-03-09
Director of Finance/CFO 58 21-08-15
Members of the board TitleAgeSince
Director/Board Member 57 22-10-28
Director/Board Member 58 20-10-31
Director/Board Member 58 20-06-15
More insiders
Date Price Change Volume
24-03-28 4.78 -1.44% 3 615 171
24-03-27 4.85 +2.97% 3,836,391
24-03-26 4.71 -2.08% 5,216,895
24-03-25 4.81 +2.34% 3,588,092
24-03-22 4.7 -0.42% 2,803,893

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company has developed and begun commercialization of its lead product, NVX-CoV2373, which is a COVID-19 vaccine. NVX-CoV2373 has received approval, interim authorization, provisional approval, conditional marketing authorization (CMA), and emergency use authorization (EUA) from multiple regulatory authorities globally for both adult and adolescent populations as a primary series and for both homologous and heterologous booster indications in over 40 countries. It is also developing an influenza vaccine candidate, quadrivalent nanoparticle influenza vaccine (qNIV); a COVID-19-Influenza Combination (CIC) vaccine candidate; and additional vaccine candidates, including a COVID-19 variant strain-containing monovalent or bivalent formulation. In addition, its other areas of focus include respiratory syncytial virus (RSV) and malaria.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
4.85 USD
Average target price
15.4 USD
Spread / Average Target
+217.53%
Consensus
  1. Stock
  2. Equities
  3. Stock Novavax, Inc. - Nasdaq